We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bristol-Myers Squibb Completes Acquisition of Medarex

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bristol-Myers Squibb Completes Acquisition of Medarex"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Bristol-Myers Squibb Company has announced that it has completed its previously announced $2.4 billion acquisition of Medarex, Inc. As a result of the transaction, Medarex has become a wholly-owned subsidiary of Bristol-Myers Squibb.

Bristol-Myers Squibb initiated on July 28, 2009 a cash tender offer to purchase all outstanding shares of common stock of Medarex for $16.00 per share.

The tender offer period expired at midnight (New York City time) on August 26, 2009, and the subsequent offering period relating to the tender offer expired at midnight (New York City time) on August 31, 2009, at which time shareholders of Medarex had tendered in aggregate approximately 120,417,467 shares of Medarex common stock which, together with the 2,879,223 shares of Medarex common stock owned by Bristol-Myers Squibb since January 2005, represented approximately 90.7% of the Medarex shares outstanding.

Today, Bristol-Myers Squibb acquired all of the remaining outstanding shares of Medarex common stock by means of a “short form merger” in which all such shares were converted into the right to receive $16.00 per share, in cash and without interest, less any required withholding taxes.